Roger K Cady, Age 7316810 72Nd Ave NE, Bothell, WA 98028

6416472, Jul 9, 2002

May 16, 2000

09/571990

Roger K. Cady - Ozark MO
Kathleen U. Farmer - Ozark MO

Edus Inc. - Springfield MO

A61B 500

600300, 600544, 128920

A method for measuring cognitive efficiency uses the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; and Mathematical Processing Task. A device for measuring cognitive efficiency includes a microprocessor having a memory; the aforementioned cognitive tests loaded into the memory; a baseline stored in the memory, means for computing the score on a run of these tests and for storing the score in the memory; the means for computing being operative for comparing the score to the stored baseline; and means for indicating a cognitive change from the baseline. Changes in cognitive efficiency may be measured by comparing the results of the cognitive tests to a baseline.

7189753, Mar 13, 2007

May 22, 2000

09/575277

Roger K. Cady - Ozark MO, US
Donna Lee Gutterman - Research Triangle Park NC, US
Stephen Venson O'Quinn - Research Triangle Park NC, US

A61K 31/405
A61K 31/335
A61K 31/34

514415, 514449, 514461, 514473, 600300

A method of preventing the headache phase of migraine in a human comprises administration of a 5HTreceptor agonist or administration of an over-the-counter or nonprescription drug to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the 5HTagonist or over-the-counter or nonprescription drug. There is disclosed a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task; and interpreting the results as a percent of baseline indicator of need for prophylaxis.

2004024, Dec 9, 2004

Mar 24, 2004

10/808008

Roger Cady - Springfield MO, US

A61K038/43
A61K039/08

424/239100

A method of treating migraine and other disorders associated with the release of certain neurotransmitters from sensory neurons includes the steps of preparing a medicament comprising Botulinum toxin type A as active-ingredient and applying the medicament transdermally to a human exhibiting symptoms associated with migraine or another sensory neuron related disorder. A pharmaceutical composition for transdermal application comprising Botulinum toxin type A as active-ingredient for administration to a human exhibiting symptoms of migraine or another sensory neuron related disorder is also provided.

2007002, Jan 25, 2007

Mar 14, 2003

10/569148

Roger Cady - Ozark MO, US

A61K 31/7008
A61K 31/58
A61K 31/55
A61K 31/4166
A61K 31/425

514023000, 514217000, 514373000, 514389000, 514561000, 514176000

A method of preventing the headache phase of migraine in a human comprises administration of an anti-convulsant medication to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the anti-convulsant. There is also disclosed a pharmaceutical composition for the prevention of the headache phase of a migraine containing an anti-convulsant as an active ingredient. There is also disclosed a method of determining prodromal symptoms of migraine using the following cognitive tests: Simple Reaction Time (); Running Memory Continuous Performance Task (); Matching to Sample (); Mathematical Processing Task (); and interpreting the results as a percent of baseline indicator of need for prophylaxis.

2007008, Apr 19, 2007

Nov 8, 2006

11/557771

Roger Cady - Ozark MO, US
Donna Gutterman - Research Triangle Park NC, US
Stephen O'Quinn - Research Triangle Park NC, US

A61K 31/60
A61K 31/522
A61K 31/415
A61K 31/405
A61K 31/19
A61K 31/16
A61K 31/192

514165000, 514263310, 514263320, 514406000, 514570000, 514420000, 514471000, 514629000

A method of preventing the headache phase of migraine in a human comprises administration of a 5HTreceptor agonist or administration of an over-the-counter or nonprescription drug to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the 5HTor over-the-counter or nonprescription drug. There is disclosed a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task; and interpreting the results as a percent of baseline indicator of need for prophylaxis.

2008012, May 29, 2008

Sep 27, 2007

11/862252

Roger K. Cady - Ozark MO, US

G01N 27/26
G01N 27/28

205792, 20440301

A biometric testing and monitoring device includes a biosensor with a substrate having an electrical impedance and a coating, at least a first antibody corresponding to at least a first biological marker on said coating, the antibody being operative for binding with the biological marker present in a sample of saliva from a human patient; and a microprocessor in communication with the biosensor and a network. In an alternate embodiment, the device also includes a cognitive testing module in communication with the microprocessor.

2008016, Jul 3, 2008

Sep 28, 2007

11/863369

Roger K. Cady - Ozark MO, US

C12Q 1/40
G01N 33/543
G01N 33/566

435 22, 436518, 436501

A diagnostic test for head and facial pain includes providing a series of antibodies to several biological markers on a test strip, collecting a sample of saliva, and applying the saliva sample to the series of antibodies. If one or more of the anticipated biological markers are present in the sample of saliva, those markers bind to their correlating antibodies thereby providing an indicator of the presence and amount of a particular biological marker in the patient's saliva upon evaluation of the test strip. When applied to a suitable biosensor, the described method can generate an electrical signal that can subsequently be transmitted to other devices. The biosensor includes a substrate that is coated with D-poly lysine on which the various antibodies are randomly arranged. The interaction of biological marker and antibody alters the electrical impedance of the substrate.

2008018, Aug 7, 2008

Dec 14, 2007

11/956580

Roger K. Cady - Ozark MO, US

G09B 19/00
C12M 1/34

434236, 4352872

A cognitive testing and assessment system includes a testing module, said testing module having an input device, a memory, and at least one cognitive test battery stored in said memory, a wireless communication module, and an assessment and response module. The wireless communication module allows the system to communicate with external devices or networks, such as the Internet, local area networks, wide area networks, satellites, or cellular networks, without a wired connection. The assessment and response center may be either integrated into the system or located in a remote centralized or regional facility that the system accesses via the wireless communication module.